icotinib + befotertinib placebo

This is a combination regimen consisting of the active drug icotinib and a placebo for befotertinib. Icotinib is an orally administered small molecule that acts as a highly selective first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI). It competitively inhibits the ATP binding site of EGFR, blocking downstream signaling pathways involved in cell proliferation and survival. Icotinib is primarily indicated for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations and has demonstrated efficacy in both advanced/metastatic settings and as adjuvant therapy after tumor resection. The "befotertinib placebo" component refers to an inert substance used as a control in clinical trials evaluating combinations or sequencing with befotertinib; it does not have pharmacological activity.

Brand names

Conmana

Other names

icotinib hydrochlorideicotinib HCl